logowsbdaily | Tue, 28 Jun 2022 07:26:28 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Revive Therapeutics Ltd.
(RVVTF)

Revive Therapeutics Ltd.
The Canadian Venture Building
82 Richmond Street East
Toronto, ON M5C 1P1
Canada
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the tre... Read More

Summary & Charts

Price$ 0.36+0.01 (+2.86%)
Day's Range$ 0.32 - 0.37 
Previous Close$ 0.35
Market Cap$ 115.22M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeOther OTC
IndustryDrug Manufacturers—Specialty & Generic
SectorHealthcare
Volume733.00K
Avg. Volume (20 day)832.38K
Rel. Volume (20 day)1.22
Rel. Volume (3 month)1.21
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Jun 06, 2022$ 0.35$ 0.37$ 0.32$ 0.36+0.01707,7001.221.211
Jun 03, 2022$ 0.31$ 0.36$ 0.31$ 0.35+0.02492,3000.890.81
Jun 02, 2022$ 0.36$ 0.37$ 0.32$ 0.33-0.02665,5001.221.081
Jun 01, 2022$ 0.34$ 0.38$ 0.34$ 0.35-0.00433,6000.830.71
May 31, 2022$ 0.38$ 0.38$ 0.34$ 0.36+0.031,087,5002.121.801
May 27, 2022$ 0.37$ 0.37$ 0.32$ 0.33-0.02471,0000.990.791
May 26, 2022$ 0.32$ 0.35$ 0.29$ 0.34+0.062,044,0004.293.432
May 25, 2022$ 0.30$ 0.30$ 0.28$ 0.28+0.00261,7000.680.451
May 24, 2022$ 0.30$ 0.30$ 0.26$ 0.28-0.02376,0000.950.651
May 23, 2022$ 0.33$ 0.33$ 0.29$ 0.30-0.00113,7000.270.201
May 20, 2022$ 0.31$ 0.32$ 0.29$ 0.30+0.01314,1000.730.54
May 19, 2022$ 0.24$ 0.29$ 0.24$ 0.29+0.051,454,6003.212.50
May 18, 2022$ 0.22$ 0.24$ 0.21$ 0.24+0.02250,5000.580.44
May 17, 2022$ 0.22$ 0.24$ 0.22$ 0.22-0.00170,1000.340.30
May 16, 2022$ 0.17$ 0.24$ 0.17$ 0.22+0.04485,1000.830.84
May 13, 2022$ 0.17$ 0.19$ 0.17$ 0.18+0.01203,5000.340.35
May 12, 2022$ 0.17$ 0.18$ 0.16$ 0.17-0.01317,6000.520.54
May 11, 2022$ 0.18$ 0.18$ 0.17$ 0.18-0.00178,0000.250.30
May 10, 2022$ 0.18$ 0.21$ 0.17$ 0.18-0.02977,9001.251.64
May 09, 2022$ 0.20$ 0.22$ 0.19$ 0.20-0.02619,8000.791.05

News

The latest news about Revive Therapeutics Ltd. (RVVTF).

Proactive Investors | 2022-06-06 14:43:38
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has updated further on its Phase 3 clinical trial for Bucillamine in coronavirus (COVID-19), saying it has now submitted a Data Access Plan to the US Food and Drug Administration (FDA), in a bid to amend the parameters of the study. As reported in late May, the firm received positive comments from the FDA over its request to determine and agree on new primary efficacy endpoints.
Proactive Investors | 2022-05-31 08:43:45
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) has announced plans to advance its drug pipeline for inflammatory liver disorders in light of the growing number of cases of acute hepatitis in children reported by the World Health Organization (WHO). Between April 5 and May 26, 2022, 650 probable cases of acute hepatitis of unknown aetiology in children across 33 countries have been reported to the WHO, according to Revive.
Proactive Investors | 2022-05-26 11:19:47
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has received positive comments from the Food and Drug Administration (FDA) regarding the company's request to determine and agree on new primary efficacy endpoints for its Phase 3 clinical trial to evaluate the safety and effectiveness of bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild-to-moderate coronavirus (COVID-19). The potential new primary efficacy endpoints include the rate of sustained clinical resolution of symptoms of COVID-19 which the company said addresses the shift in COVID-19 clinical outcomes observed over the course of the pandemic and, therefore, are more meaningful study endpoints for the FDA to consider to potential Emergency Use Authorization.
Proactive Investors | 2022-05-16 12:40:54
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced that it has submitted a request to the US Food & Drug Administration (FDA) to determine and agree on the potential new primary efficacy endpoints of the company's Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate coronavirus (COVID-19). The researcher and developer of therapeutics for infectious diseases and rare disorders said the potential new primary efficacy endpoints include the rate of sustained clinical resolution of symptoms of COVID-19 that addresses the shift in COVID-19 clinical outcome observed over the course of the pandemic and, therefore, to have more meaningful study endpoints for the FDA to consider for potential Emergency Use Authorization (EUA).
Proactive Investors | 2022-04-26 06:48:03
Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) said it has been in discussions with the Biomedical Advanced Research and Development Authority (BARDA) to explore the potential of securing advanced development and possible commercial scale-up funding for Bucillamine, its COVID-19 oral drug. In an update on Phase 3 of its US Food & Drug Administration (FDA) clinical trial to evaluate the safety and efficacy of Bucillamine, the Toronto-based company said discussions surrounding Bucillamine's attributes and clinical potential were determined to be relevant for consideration, which could provide support to the company's current efforts.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-05-30AMC------------
2022-03-01AMC------------
2021-11-29AMC------------
2021-05-31BMO------------

Top Discussions

These are the top discussions over the last 24-hours that mention the RVVTF stock ticker symbol.


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 14 Dec 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.